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Abstract
Summary Combined treatment with alendronate and
eldecalcitol was found to be more effective in reducing the
bone turnover markers and increasing bone mineral density
than alendronate treatment with vitamin D3 and calcium
supplementation in the osteoporotic patients.
Introduction We compared the clinical efficacy and safety
of combined treatment with alendronate plus eldecalcitol
(ALN + ELD) with those of treatment with ALN plus
vitamin D and calcium (ALN + VitD).
Methods Osteoporotic 219 patients were randomly assigned
to the ALN + ELD, or the ALN + VitD group. Primary
endpoint was the inter-group differences in lumbar spine
BMD (L-BMD) at patient’s last visit. Secondary endpoints
included the differences in BMD at other sites and the bone
turnover marker (BTM) levels.
Results L-BMD, total hip BMD and femoral neck (FN-BMD)
increased from baseline by 7.30, 2.41, and 2.70 % in the ALN
+ ELD group, and by 6.52, 2.27, and 1.18 % in the ALN +
VitD group, respectively. Inter-group differences of the L-
BMD and total hip BMD values were not significant. The
increase of the FN-BMD was larger in the ALN + ELD group
than the ALN + VitD group. Reductions of the BTMs were
greater in the ALN + ELD group than the ALN + VitD group.
Interaction of the percent increase of the L-BMD with the
baseline values of the BTMs was observed in the ALN + VitD
group only. The increases of the FN-BMD in patients with
lower baseline values of type-I-collagen C-telopeptide
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(sCTX) and serum 25(OH) D levels <20 ng/mL were signif-
icantly larger in the ALN + ELD group than the other group.
Conclusion Combination treatment of ALN plus ELD was
more effective in reducing the BTMs and increasing the FN-
BMD than ALN treatment with vitamin D3 and calcium.
Keywords Bisphosphonate . Bonemineral density .
Bone turnovermarkers . Eldecalcitol . VitaminD
Introduction
Eldecalcitol (ELD) is a newly developed active vitamin D
analog, bearing a hydroxypropyloxy substituent at the 2β
position of 1α,25(OH)2D3 (calcitriol) [1]. In a randomized,
placebo-controlled, double-blind clinical trial conducted in
patients with osteoporosis receiving vitamin D supplementa-
tion, 48-week treatment with ELD increased the lumbar spine
and total hip bonemineral density (BMD) in a dose-dependent
manner without causing sustained hypercalcemia [2]. In a
fracture prevention trial, 3-year treatment with ELD signifi-
cantly reduced the incidence of vertebral and wrist fractures to
the greater extent than treatment with alfacalcidol, which is
1α-hydroxyvitamin D3; the incidence of adverse events dur-
ing the trial was similar between the two treatment groups [3].
Based on these results, ELD has been approved for the treat-
ment of osteoporosis in Japan.
Drugs of the bisphosphonate (BP) group have been
used as potent therapeutic agents in the treatment of
osteoporosis [4, 5]. BPs increase the BMD and suppress
bone turnover by inhibiting osteoclastic activity and
inducing apoptosis of osteoclasts. They bind strongly
to the bone and remain in the bone for prolonged
periods of time. Serum calcium (Ca) decreases slightly
during BP treatment due to a reduction of the Ca efflux
from the bone. Because even subtle reduction of the
serum Ca causes an increase in the secretion of para-
thyroid hormone (PTH), which enhances bone turnover,
the Ca balance in the body becomes negative if BP-
treated patients have vitamin D insufficiency or defi-
ciency. Therefore, it is generally accepted that during
the treatment of osteoporosis with BPs, vitamin D and
Ca supplementation is necessary to enhance the efficacy
of the BP treatment and prevent negative Ca balance in
the body. We hypothesized that the addition of active
vitamin D in place of vitamin D plus Ca to BP therapy
may be more effective to increase the BMD and regu-
late the bone turnover. In this study, we compared the
clinical efficacy and safety of addition of ELD in com-
parison to that of plain vitamin D plus Ca in patients
with primary osteoporosis receiving alendronate (ALN)
treatment.
Subjects and methods
All procedures performed in studies involving human partic-
ipants were in accordance with the ethical standards of the
institutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or com-
parable ethical standards.
Study design and patients
The e-ADVANCED (Eldecalcitol; Alendronate plus vitamin
D Versus AleNdronate Combined with ElDecalcitol) study
was a randomized, unblinded clinical trial carried out to assess
the efficacy on BMD, bone turnover markers (BTMs) and
safety, of addition of ELD as compared to that of vitamin D
plus Ca supplementation in osteoporotic patients receiving
weekly ALN treatment (JapicCTI-No.111653). We analyzed
the data of 219 subjects, including 214 females and 5 males,
ranging in age from 60 to 90 years (yr.) (mean, 71.5 yr.), who
had osteoporosis (defined as a low BMD (70 % of the young
adult mean (YAM); 0.708 g/cm2 by the Hologic QDR series)
or osteopenia (80 % of the YAM; 0.809 g/cm2 by the Hologic
QDR series) with at least one vertebral fracture, according to
the criteria of the Japanese Society for Bone and Mineral
Research [6]. Prevalent vertebral fractures were assessed by
x-ray examination of the vertebrae, and diagnosed according
to the criteria of the Japanese Society for Bone and Mineral
Research [7]. All the subjects were 60 years old or older, and
patients were excluded from the study if they had fractures in
any of the lumbar vertebrae L2–L4 or had disorders such as
primary hyperparathyroidism, Cushing’s syndrome, gonadal
insufficiency, poorly controlled diabetes mellitus, or other
causes of secondary osteoporosis, or a history of/suspected
active urolithiasis at any time. Subjects were also excluded if
they had taken BPs within 48 weeks before entry into this
study, taken glucocorticoids, calcitonin, vitamin K, active
vitamin D compounds, ipriflavones, selective estrogen recep-
tor modulators, or hormone replacement therapy within
8 weeks prior to entry into this study, or taken PTH, anti-
receptor activator of NF-kappaB ligand (RANKL) antibody,
cathepsin K inhibitor prior to entry, had serum calcium levels
above or below the normal range, serum creatinine levels of
over 1.0 mg/dL, any disorder associated with delayed passage
of food through the esophagus, received/were scheduled to
receive any invasive dental procedures, clinically significant
hepatic or cardiac disorders, or active malignant tumor or prior
therapy for malignancy within the previous 3 years. The
subjects were enrolled at 13 centers in Japan. The study was
conducted with the approval of the institutional review board
at each center and in accordance with the Declaration of
Helsinki and the Japanese of Good Clinical Practice
Guidelines. Written informed consent was obtained from each
patient prior to any study-related procedure.
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Treatment
Patients were randomly assigned at a 1:1 ratio to receive oral
ALN at the dose of 35 mg weekly, the approved dosage in
Japan, plus oral ELD at the dose of 0.75 μg daily (ALN +
ELD group), or oral ALN at the dose of 35 mg weekly with
oral vitamin D 400 IU + Ca 610 mg daily (ALN + VitD
group). Randomization was performed by a computerized
system. The subjects were stratified into groups on the basis
of the L2-4 BMD values (≥70 %YAM/<70 %YAM). The
randomization sequence was created by the person responsi-
ble for the investigational product randomization. Neither the
patients nor the investigators were blinded to the treatment
assignment at any time during the study period. Compliance
with the study treatment was assessed based on the medication
diaries maintained by each subject.
Assessments
The BMD values at the lumbar spine (L-BMD), femoral neck
(FN-BMD) and total hip in the posterior-anterior projections
were measured at the baseline and at 24 and 48weeks by dual-
energy x-ray absorptiometry (DXA). The 13 study centers
participating in this trial were all equipped with the Hologic
QDR series (QDR2000, QDR4500, Explorer, Delphi or
Discovery, Hologic, Inc.) for the BMD measurements. A
central facility (Department of Radiological Technology,
Kawasaki College of Allied Health Professions) performed
quality assurance of the longitudinal adjustment. Adjustment
for DXA machine differences was made to calibrate each
machine with standardized phantoms. All the DXA measure-
ments were analyzed at a central site by a radiologist who was
blinded to the treatment group assignment. Radiographs of the
thoracic and lumbar spine were taken at the baseline and at
48 weeks to assess the incidence of vertebral fractures. To
identify morphometric vertebral fractures, the vertebral bodies
in the lateral projections from Th4 to L4 were quantitated
using a semi-quantitative (SQ) methodology [8] by a central
committee who was also blinded to the treatment assessment.
Patients with more than one incident L2–L4 vertebral fracture
during the treatment period were excluded from the BMD
analysis. Hip BMD images not satisfying the appropriate
positioning criteria were also excluded by the central
committee.
Serum and postprandial urine samples were collected at the
baseline and at 4, 12, 24, and 48 weeks of treatment to
evaluate Ca-related parameters such as the serum Ca, serum
phosphorus, serum albumin, serum creatinine, and urinary Ca
adjusted by mg/dL GF. In addition, routine blood biochemical
analyses, including evaluation of the hematological, hepatic,
and renal functions were conducted at the baseline and at 24
and 48 weeks. Bone turnover markers, including type I
Table 1 Baseline characteristics
of the enrolled patients ALN + ELD group
(n=110)
ALN + VitD group
(n=109)
Age (years) 71.5±7.3 71.6±6.6
Gender (female/male) 109/1 105/4
Height (cm) 150.0±5.9 149.8±6.3
BMI (kg/m2) 22.3±3.1 21.7±2.9
Number of prevalent vertebral fractures
0 54 (50.9 %) 37 (36.6 %)
1 34 (32.1 %) 41 (40.6 %)
≥2 16 (15.1 %) 21 (20.8 %)
LS-BMD (mg/cm2) 653±77 655±90
Total hip BMD (mg/cm2) 666±82 659±95
FN-BMD (mg/cm2) 518±70 518±84
sCa (mg/dL) 9.43±0.32 9.46±0.34
uCa (mg/dL GF) 0.099±0.073 0.103±0.067
BAP (μg/L) 19.6±7.6 18.6±7.4
P1NP (ng/mL) 54.8±22.2 57.1±26.9
TRACP-5b (mU/dL) 494±160 526±193
uNTX (nmol BCE/mmol Cr) 68.2±27.3 70.0±30.2
sCTX (pmol/mL) 4.30±2.09 4.55±2.33
25(OH) D (ng/mL) 18.7±6.2 19.2±6.7
1,25(OH)2D (pg/mL) 62.4±26.8 58.6±25.7
Intact-PTH (pg/mL) 50.4±17.6 50.8±15.2
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collagen C-telopeptide (sCTX) (β-Crosslaps N, Fujirebio Inc,
Tokyo), urinary type I collagen N-telopeptide (uNTX)
(Osteomark NTx; Alere, Orlando, FL), tartrate-resistant acid
phosphatase 5b (TRACP-5b) (Osteolinks TRAP-5b, DS
Pharma Biomedical Co., Ltd, Osaka), serum bone-specific
alkaline phosphatase (BAP) (Access Ostase, Beckman
Coulter, Inc., Brea, CA), and amino-terminal propeptide of
type 1 procollagen (P1NP) (Procollagen Intact P1NP, TFB
Inc. Tokyo) were assessed at the baseline and at 12, 24, and
48 weeks. Blood levels of the calcium-regulating hormones
such as intact PTH (Intact-PTH, Roche Diagnostics,
Hoffmann-La Roche Ltd, Indianapolis, IN), 25(OH) D
(CPBA, LSI Medience Corporation, Tokyo), and 1,
25(OH)2D (1,25(OH)2D RIA Kit [TFB], Fujirebio Inc.,
Tokyo) were also evaluated at the baseline and at 24 and
48 weeks.
All the patients were asked about the occurrence of any
adverse events at each visit, and all adverse events were
analyzed, regardless of the investigators’ assessments of the
causality. The Medical Dictionary for Regulatory Activities
(MedDRA, version 16.1) was used to categorize the reported
adverse events.
Statistical analyses
The primary endpoint was the percent change of the lumbar
spine BMD (L-BMD) at the patient’s last visit, week 48 from the
baseline. Analyses were performed according to the intent-to-
treat principle, in which all randomized patients who had taken at
least one dose of the study drug and had undergone both a
baseline and at least one post-randomization measurement of
the BMD, bone markers, and other parameters were included.
Missing data were imputed by the last observation carried for-
ward (LOCF) method. ANCOVA adjusted for the baseline data
was used between the ALN + ELD and ALN + VitD groups.
Significance level is used 5 % for two-sided p value. As explor-
atory analysis, group means and 95 % confidence intervals are
calculated for the percent changes from the baseline in the
lumbar, total hip and femoral neck BMD, and were used to
assess the changes within each group for each visit. The rela-
tionships between the variables were assessed by calculation of
the Pearson’s correlation. Multiplicities adjustments are not used
for p values of exploratory analysis.
Results
Patient distribution and baseline characteristics
A total of 230 patients were enrolled, of which 11 patients did
not receive any treatment; the remaining 219 patients were
included in the full analysis set (FAS). The patients were
randomized to the ALN + ELD (n=110) or ALN + VitD
(n=109) group. The study was completed as per protocol in
196 patients (PPS; 101 patients in the ALN + ELD group and
95 patients in the ALN + VitD group). The baseline charac-
teristics were well-balanced between the two treatment groups
(Table 1). The mean serum 25(OH) D level at the baseline was
18.7 ng/mL (66.7 % of the subjects with values <20 ng/mL) in
the ALN + ELD group, and 19.2 ng/mL (61.4 % of the
subjects with values <20 ng/mL) in the ALN + VitD group.
Bone mineral density and BTMs
The L-BMD, total hip BMD, and FN-BMD increased from
baseline significantly by 7.30, 2.41, and 2.70 %, on average,



















































































Fig. 1 Percent change from the baseline of the a lumbar spine BMD, b
total hip BMD, and c femoral neck BMD. Symbols indicate the groups as
follows: ALN + ELD, closed circles (•); ALN + VitD, open circles (○).
Data are represented as least squares (LS) mean±standard error (SE)
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ALN + VitD group, respectively, at 48 weeks (Fig. 1a–c).
Inter-group differences in the L-BMD and total hip BMD
values were not significant. The percent increases in the FN-
BMD were markedly larger in the ALN + ELD group than
those in the ALN + VitD group at 48 weeks (p=0.011).
Substantial decrease in the levels of all BTMs (sCTX,
uNTX, TRACP-5b, BAP, and P1NP) was observed from
12 weeks onward in both treatment groups, as compared to
the respective baseline levels (Fig. 2a–e). The changes from
the baseline of all the BTMs were larger in the ALN + ELD
group at 12 weeks onwards than the corresponding changes in
the ALN + VitD group.
BMD changes in relation to the baseline values of the BTMs
and serum 25(OH) D
Pearson’s correlation analyses revealed that the percent in-
crease of the L-BMDwas strongly correlatedwith the baseline
levels of all the BTMs in the ALN + VitD group (Table 2), but
not in the ALN + ELD group. Then, patients were stratified
into tertiles by the baseline levels of the BTMs. In the ALN +
VitD group, the percent increase of the L-BMD was larger in
the high BTM tertile and smaller in the low BTM tertile
(Fig. 3a–e). In the ALN + ELD group, however, the percent
BMD increase did not depend on the baseline levels of the
BTMs. The percent increases of the L-BMD in patients with





























































































































































Fig. 2 Percent changes from the
baseline of the levels of a sCTX,
b uNTX, c TRAC-5b, dBAP, and
e P1NP. Symbols indicate the
groups as follows: ALN + ELD,
closed circles (•); ALN + VitD,
open circles (○). Data are
represented as LS mean±SE
Table 2 Correlations between the percent change of the lumbar spine
BMD and the baseline values of the BTMs
ALN + ELD group (n=105) ALN + VitD group (n=101)
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were significantly larger in the ALN + ELD group than those
in the ALN + VitD group. The increases of the FN-BMD in
patients with lower baseline values of sCTX were significant-
ly larger in the ALN + ELD group than those in the ALN +
VitD group (Fig. 4).
Patients were also stratified by the baseline serum 25(OH) D
levels into two groups (<20 ng/mL or ≥20 ng/mL). There was
no correlation between the percent increase of the L-BMD and
the baseline serum 25(OH) D level in either group (Fig. 5a). On
the other hand, the percent increase of the FN-BMD was
markedly higher in the patients with serum 25(OH) D levels
<20 ng/mL in ALN + ELD group as compared to that in the
ALN + VitD group (Fig. 5b).
Fracture incidences and falls
The cumulative incidence of new vertebral fractures during
the 48-week treatment period was 6.3 % (n=7 out of 110) in
the ALN+ ELD group and 4.6% (n=5 out of 109) in the ALN
+ VitD group. The incidence of osteoporotic non-vertebral
Low Middle High
414.0<)Lm/gn(XTCs ≥0.414 - <0.635 ≥0.635
uNTX (nmol BCE/mmol Cr) <54.8 ≥54.8 - <74.8 ≥74.8
TRACP-5b (mU/dL) <412 ≥412 - <557 ≥557
BAP (µg/L) <15.0 ≥15.0 - <21.2 ≥21.2
5.14<)Lm/gn(PN1P ≥41.5 - <62.7 ≥62.7





















































































































34    31 34    37 37    33
low middle high
32    33 38    33 35    35
low middle high
38    27 33    37 34    37
low middle high
38    30 32    37 35    34
low middle high
38    30 40    30 27 41
low middle high
Fig. 3 Percent changes of the
lumbar spine BMD from the
baseline at 48 weeks. Black bars
indicate the ALN + ELD group;
white bars indicate the ALN +
VitD group. Data are represented
as LS mean±SE. Patients were
stratified into tertiles according to
the baseline levels of the BTMs: a
sCTX, b uNTX, c TRACP-5b, d
BAP, and e P1NP. The number
below each bar represents
number of patients of each group
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fractures was 0.0 % (n=0/110) in the ALN + ELD group and
4.6 % (n=5/109) in the ALN + VitD group. The cumulative
incidence of self-reported falling during the 48-week treat-
ment period was 24.5% (n=27/110) in the ALN + ELD group
and 29.4 % (n=32/109) in the ALN + VitD group, with no
significant difference between the two groups.
Adverse events
The total incidence of adverse events during the study period
was 86.4 % (95/110, 280 events) in the ALN + ELD group,
and 86.2 % (94/109; 271 events) in the ALN + VitD group.
The adverse events are listed in Table 3. No clinically mean-
ingful changes of the laboratory data, including the blood
biochemical, hematological or urine exam data were detected
during the study period (not shown). No significant changes
of the mean serum calcium or urinary calcium excretion levels
from the baseline were observed in either the ALN + ELD
group or the ALN + VitD group at any time-point during the
study period (not shown). Overall, no significant differences
were observed between the two groups with respect to the
incidence/severity of any adverse events.
Discussion
ALN and ELD were found to exert additive anti-resorptive
effects in patients with osteoporosis in this study. ALN re-
duces bone resorption by suppressing osteoclast activity and
inducing osteoclast apoptosis via inhibition of farnesyl pyro-
phosphate synthetase in the cells [5]. On the other hand, it has
been observed that ELD reduces the osteoclast number by
suppressing the expression of RANKL in the osteoblasts [9],
stimulating differentiation of preosteoblasts to osteoblasts [10]
and shifting osteoclast precursor cells to the blood circulation
[11]. Recent studies have unraveled that microRNAs regulate
osteoclast [12] and osteoblast differentiation [13], and may be
involved in the epigenetic regulation of target genes by vita-
min D [14, 15]. These apparently different anti-resorptive
actions at the cellular and molecular levels of ALN and ELD
may be able to work synergistically in reducing the bone
turnover in men and postmenopausal women with
osteoporosis.
The effect of combined treatment with ALN and ELD on
the FN-BMD, namely, a 2.7 % increase of the BMD over the
treatment period of 48 weeks, seemed to be clinically impor-
tant. In fact, the increase of the FN-BMD associated with
bisphosphonate treatment plus vitamin D and calcium supple-
mentation is reportedly minimal and usually less than 2.0 % in
a year, e.g., 0.4–1.8 % for ALN, 0.7 % for ibandronate, and
0.0 % for risedronate [16–21]. However, more potent anti-
resorptive agents such as denosumab [22] and odanacatib [23]
produced a more pronounced increase of the FN-BMD, by
approximately 2.7 and 2.5 %, respectively, in 1 year. Thus, the
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27    26 27    31 28    28
low middle high
Fig. 4 Percent changes of the femoral neck BMD from the baseline at
48 weeks. Black bars indicate the ALN + ELD group;white bars indicate
the ALN + VitD group. Data are represented as LS mean±SE. Patients
were stratified into tertiles according to the baseline sCTX levels. The
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Fig. 5 Percent changes from the
baseline of the a lumbar spine
BMD and b femoral neck BMD
at 48 weeks. Black bars indicate
the ALN + ELD group; white
bars indicate the ALN + VitD
group. Data are represented as LS
mean±SE. Patients were stratified
into two groups according to the
baseline serum 25(OH) D levels
(<20 ng/mL or ≥20 ng/mL). The
number below each bar
represents number of patients of
each group
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FN-BMD may be comparable with that of these potent anti-
resorptive agents, at least over a treatment period of 1 year.
The synergistic effects of ALN and ELD in reducing the
bone turnover (anti-resorptive activity) could be one of the
reasons to explain the efficacy of combined ALN plus ELD
therapy on the BMD. The degree of reduction in the levels of
the BTMs during ALN treatment has been shown to be
correlated with the long-term BMD response [24–27]. Thus,
enhancement of the anti-resorptive activity of ALN by the
addition of ELD may contribute to the increase of the BMD.
Another explanation is the potent Ca-mobilizing action of
ELD. ELD has been shown to be comparable to the active
form of vitamin D3, such as 1α-hydroxyvitamin D3 or 1α,
25(OH)2D3 [28–30], in stimulating Ca transport in the intes-
tine. It has also been observed that ELD is more efficacious in
enhancing bone mineralization than plain vitamin D3 in ro-
dent models of vitamin D deficiency [31, 32]. Thus, the potent
activity of ELD in stimulating intestinal Ca absorption may
account for its stronger effect on the BMD, especially the FN-
BMD, in patients with low baseline serum 25(OH) D levels.
It has been observed that the baseline levels of the BTMs
influence the increase of the L-BMD and hip BMD occurring
following ALN treatment. In fact, patients with high baseline
levels of the BTMs tended to show a greater percent increase
of the BMD than patients with low baseline levels of the
BTMs at the start of the ALN treatment in the Fracture
Intervention Trial [33]. This study also confirmed the strong
correlation with the percent increase of the L-BMD in ALN +
VitD group. However, combined treatment with ALN + ELD
weakened the relationship. Actually, differences in percent
increase values of L-BMD and F-BMD were not apparent
between the high and the low tertile subgroups of BTMs in
ALN + ELD group, compared to the inter-subgroup differ-
ences in ALN + VitD group. The increased potency of reduc-
ing bone turnover and intestinal Ca absorption by the combi-
nation of ALN and ELD may be related to the findings.
This study had several limitations. It was not a double-
blind study, and both the investigators and patients were aware
of the treatment assigned to the patients. Inter-group differ-
ences in the changes of the L-BMD, which provided the basis
for the power calculation in the study, were not statistically
significant. The safety profile did not differ between the
groups in this study, but the size of the study population and
duration of the study were not large/long enough to compare
the incidences of rare adverse events. This study was not
powered to detect the incidences on fractures and falls be-
tween the groups either.
In conclusion, combined treatment with 35 mg of ALN
weekly and 0.75 μg of ELD daily for 48 weeks was found to
be more effective in reducing the BTMs in Japanese men and
Table 3 Incidences of adverse events
ALN + ELD group (n=110) ALN group (n=109)
N (%) N (%)
Any adverse events 95 (86.4 %) 94 (86.2 %)
Infection 50 (45.5 %) 41 (37.6 %)
Injury, poisoning, and procedural complications 38 (34.5 %) 43 (39.4 %)
Musculoskeletal and connective tissue disorders 33 (30.0 %) 36 (33.0 %)
Gastrointestinal disorders 28 (25.5 %) 29 (26.6 %)
Skin and subcutaneous tissue disorders 15 (13.6 %) 18 (16.5 %)
Investigations 11 (10.0 %) 5 (4.6 %)
Ear and labyrinth disorders 8 (7.3 %) 1 (0.9 %)
Nervous system disorders 8 (7.3 %) 7 (6.4 %)
Respiratory, thoracic and mediastinal disorders 7 (6.4 %) 8 (7.3 %)
Eye disorders 5 (4.5 %) 11 (10.1 %)
Vascular disorders 5 (4.5 %) 2 (1.8 %)
Neoplasms benign, malignant and unspecified (including cysts and polyps) 4 (3.6 %) 3 (2.8 %)
Cardiac disorders 3 (2.7 %) 1 (0.9 %)
Metabolism and nutrition disorders 3 (2.7 %) 4 (3.7 %)
Psychiatric disorders 2 (1.8 %) 2 (1.8 %)
Blood and lymphatic system disorders 1 (0.9 %) 2 (1.8 %)
General disorders and administration site conditions 1 (0.9 %) 6 (5.5 %)
Immune system disorders 1 (0.9 %)
Reproductive system and breast disorders 1 (0.9 %) 1 (0.9 %)
Hepatobiliary disorders 1 (0.9 %)
Renal and urinary disorders 2 (1.8 %)
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postmenopausal women with osteoporosis. The combined
treatment was also found to potently increase the FN-BMD.
ELD seemed to exert additive anti-resorptive activity and
enhance the potent intestinal calcium absorption in patients
receiving ALN monotherapy for 48 weeks.
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